FGP
LENZ

Freestone Grove Partners’s LENZ Therapeutics LENZ Stock Holding History

Freestone Grove Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$18 – 1372
2026
Q1 		$18 Sell
2
-22,969
-100% -$323K ﹤0.01% 938
2025
Q4 		$368K Buy
+22,971
New +$670K ﹤0.01% 631

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Freestone Grove Partners's LENZ Position: Q2 2026 in Review

Freestone Grove Partners sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 2 shares — an estimated $18 sold.

Freestone Grove Partners first reported a position in LENZ in Q4 2025 and held it in 2 quarters. The position peaked at $368K in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Freestone Grove Partners reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 2 LENZ Therapeutics shares in Q2 2026, an estimated $18.
  • Freestone Grove Partners first reported a position in LENZ Therapeutics in Q4 2025 and held it in 2 quarters.
  • Freestone Grove Partners's LENZ Therapeutics position peaked at $368K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.